- MoonLake Immunotherapeutics (MLTX, Financial) to host a Capital Markets Day on April 29, 2025.
- Announced a $500 million non-dilutive financing agreement with Hercules Capital.
- Updates on Phase 3 VELA Program for Hidradenitis Suppurativa and Phase 2 LEDA Study for Palmoplantar Pustulosis.
MoonLake Immunotherapeutics (Nasdaq: MLTX) has scheduled a virtual Capital Markets Day for Tuesday, April 29, 2025, at 8:30 AM EST. The event, streamed live from New York, will feature presentations by CEO Jorge Santos da Silva, CSO Kristian Reich, and CFO Matthias Bodenstedt, who will discuss key financial and clinical developments.
A significant highlight will be a detailed explanation of the up to $500 million non-dilutive financing agreement with Hercules Capital. This financing is aimed at bolstering MoonLake's financial standing while supporting its clinical and commercial goals, preserving shareholder value.
The company will also provide updates on the Phase 3 VELA Program for Hidradenitis Suppurativa (HS), particularly the completion of patient recruitment and insights into baseline characteristics. Additionally, MoonLake will share an early interim readout from the Phase 2 LEDA Study in Palmoplantar Pustulosis (PPP), offering insights into the potential of the Nanobody® sonelokimab in this market.
The presentation will conclude with strategic market outlooks, including data analysis and competitor assessment. A subsequent Q&A session will allow for further discussion, and a recording of the event will be available post-broadcast. Investors and analysts can access the webcast via MoonLake's event page.
MoonLake Immunotherapeutics continues to advance its pursuit of innovative treatments for inflammatory diseases using sonelokimab, with a focus on addressing significant unmet needs in conditions like HS and psoriatic arthritis.
